◆ Market Data --:--
Commodities
Loading...
📈 Yields & Rates
Loading...
💱 FX Rates
Loading...
📈 Market Pulse
Loading...
🏛 Congress Trades
Loading...
👤 Insider Trades
Loading...
Customize Items

南模生物

南模生物
Loading...
Key Metrics
Market Cap
3.2B ($464.9M)
P/E Ratio
N/A
P/B Ratio
N/A
Revenue
381.0M
Net Income
6.5M
Gross Margin
N/A
Op. Margin
0.7%
Net Margin
1.7%
ROE
0.4%
ROA
0.3%
D/E
0.15
Dividend Yield
N/A
EPS
0.08
Current Ratio
6.56
Price History
Company Info
IndustryM73研究和试验发展
Market SegmentSTAR Market
CurrencyCNY
Fiscal Year2024
Business Overview

Shanghai Model Organisms Center, Inc. engages research and development, production, sale, and related technical services of genetically modified animal models. The company uses model organisms, such as mice, rats, zebrafish, and nematodes as carriers which uses gene editing technology to introduce or delete target DNA fragments. It offers toolbox of mice; disease mice, such as rare, infectious, and nervous system diseases, cardio-metabolic, autoimmune, and spontaneous tumor; and target humanized knockins, which includes tumor targets, immune checkpoint, complements, cytokines, and metabolic an...

Peers
工商银行
601398
2.7T
P/E: 7.6
建设银行
601939
2.5T
P/E: 7.2
农业银行
601288
2.4T
P/E: 8.7
中国海油
600938
2.0T
P/E: 16.2
宁德时代
300750
1.9T
P/E: 25.6
贵州茅台
600519
1.8T
P/E: 20.1
中国银行
601988
1.8T
P/E: 7.3
中国人寿
601628
1.2T
P/E: 6.9
Financial Statements
Loading financials...
Open Advanced Charts

Full charting with technical indicators, candlestick, and more.

About 南模生物

Shanghai Model Organisms Center, Inc. engages research and development, production, sale, and related technical services of genetically modified animal models. The company uses model organisms, such as mice, rats, zebrafish, and nematodes as carriers which uses gene editing technology to introduce or delete target DNA fragments. It offers toolbox of mice; disease mice, such as rare, infectious, and nervous system diseases, cardio-metabolic, autoimmune, and spontaneous tumor; and target humanized knockins, which includes tumor targets, immune checkpoint, complements, cytokines, and metabolic and other targets, as well as cytokine reporters, inducible cell ablation, and cell-specific reporters. The company also provides other models comprising rats, such as humanized drug target, immunodeficient, diseases, reporters, and cre-drivers; standard strains including inbred and outbred; cells model, which includes reporter labeled, primary, wild-type, and other; and supporting solutions including colony management, such as cryopreservation and cryorecovery, housing and management, genotyping analysis, and breeding services, as well as auxiliary apparatuses, such as e-BLOT WB imaging system. In addition, it offers model customization including includes gene editing technology, such as ES cell targeting, CRISPR gene editing, and transgene; genetically engineered type model, which includes conventional and conditional knockout; KO first, knock-in, point mutation, conditional point mutation, humanization, targeted conditional overexpression, and random transgene; and surgery and preconditioning. Further, the company provides preclinical services, which includes non-GLP toxicology, pharmacokinetics, phenotype analysis, and pharmacology and pharmacodynamics. It offers treatment for various therapeutic areas, such as oncology; nervous system, autoimmune, and digestive system diseases. The company was founded in 2000 and is headquartered in Shanghai, China.


Ticker688265
ExchangeSSE
Sector证监会行业分类
IndustryM73研究和试验发展
NEWS
Loading article...
NEWS
Loading news...
TRENDING
Loading...